FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362541676> ?p ?o ?g. }

• W4362541676 endingPage "6150" @default.
• W4362541676 startingPage "6150" @default.
• W4362541676 abstract "Abstract Small cell lung cancer (SCLC) is an aggressive malignancy with critical need for new therapies. While currently treated as a single disease, SCLC is heterogenous, comprised of several transcriptional subtypes. Each of these subtypes has distinct drivers and may warrant unique therapeutic targets. Two potential therapeutic targets for SCLC are the pro-survival proteins BCL-2 and BCL-XL. BCL-2 is overexpressed in ASCL1 (A) and POUF3 (P) subtypes of SCLC. We therefore sought to evaluate efficacy of the dual BCL-2/XL inhibitor AZD0466 in SCLC models and to determine whether transcriptional subtype would predict response. AZD0466 is a novel drug-dendrimer conjugate. The active moiety, AZD4320, is a potent dual inhibitor of BCL-2 and BCL-XL. AZD4320 is covalently conjugated to a 5th-generation PEGylated poly-lysine dendrimer through a hydrolytically labile linker to make AZD0466. AZD0466 has been optimized to deliver efficacy while mitigating potential Cmax-driven on-target toxicities of AZD4320. AZD4320 was active (IC50 ≤0.1 µM) in 9/27 SCLC cell lines. AZD4320 in vitro sensitivity was enriched in cell lines that represented A and P subtypes of SCLC compared to NEUROD1 and YAP1 subtypes. We next profiled AZD0466 in a panel of SCLC patient-derived models: 14 patient-derived xenografts and 10 circulating tumor cell-derived xenografts. AZD0466 monotherapy dosed weekly IV was active in 12/24 SCLC xenografts, driving regressions in 8 models. AZD0466 drove efficacy and cleaved caspase-3 induction in a dose-dependent manner. Similar to in vitro, AZD0466 in vivo efficacy was enriched in subtype-A, driving responses in 10/14 ASCL1 models (7 regression, 3 stable disease). AZD0466 response also correlated strongly with BCL-2 mRNA expression (P&lt;0.0001). AZD0466 outperformed the selective BCL-2 inhibitor venetoclax in 6/10 models. Notably, AZD0466 was active in models resistant to platinum/etoposide chemotherapy, the standard-of-care for SCLC. Together, these data suggest BCL-2/XL inhibition has therapeutic potential in SCLC. AZD0466 is in clinical development. The first-in-human study treated 9 patients with advanced solid tumors (NCT04214093) at doses from 50-200mg, all of which were well-tolerated. The BOR was SD observed in 3 patients (100mg) with 1 patient receiving treatment for 5.5 months. AZD0466 is now under evaluation in patients with hematologic malignancies (NCT04865419 and NCT05205161). AZD0466 has been dosed in 33 patients up to 2400mg. No DLTs have been reported to date. Initial clinical activity has been observed through reduction of bone marrow blasts following AZD0466 treatment. AZD0466 exhibits linear PK, consistent across solid tumor and leukemia patients. The doses tested are in line with preclinical studies in SCLC. Citation Format: Courtney L. Andersen, Giulia Fabbri, David Jenkins, Zumla Cader, Shringi Sharma, Areya Tabatabai, Srividya Balachander, Jordan Roebuck, Melanie Galvin, Kathryn Simpson, Caroline Dive, Jordi Rodon Ahnert, Jamal Saeh. AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6150." @default.
• W4362541676 created "2023-04-06" @default.
• W4362541676 creator A5001466285 @default.
• W4362541676 creator A5016948495 @default.
• W4362541676 creator A5023384189 @default.
• W4362541676 creator A5034692076 @default.
• W4362541676 creator A5047061096 @default.
• W4362541676 creator A5047636541 @default.
• W4362541676 creator A5061267813 @default.
• W4362541676 creator A5067313107 @default.
• W4362541676 creator A5070472807 @default.
• W4362541676 creator A5071750897 @default.
• W4362541676 creator A5077369314 @default.
• W4362541676 creator A5088521502 @default.
• W4362541676 creator A5088647899 @default.
• W4362541676 date "2023-04-04" @default.
• W4362541676 modified "2023-09-30" @default.
• W4362541676 title "Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models" @default.
• W4362541676 doi "https://doi.org/10.1158/1538-7445.am2023-6150" @default.
• W4362541676 hasPublicationYear "2023" @default.
• W4362541676 type Work @default.
• W4362541676 citedByCount "0" @default.
• W4362541676 crossrefType "journal-article" @default.
• W4362541676 hasAuthorship W4362541676A5001466285 @default.
• W4362541676 hasAuthorship W4362541676A5016948495 @default.
• W4362541676 hasAuthorship W4362541676A5023384189 @default.
• W4362541676 hasAuthorship W4362541676A5034692076 @default.
• W4362541676 hasAuthorship W4362541676A5047061096 @default.
• W4362541676 hasAuthorship W4362541676A5047636541 @default.
• W4362541676 hasAuthorship W4362541676A5061267813 @default.
• W4362541676 hasAuthorship W4362541676A5067313107 @default.
• W4362541676 hasAuthorship W4362541676A5070472807 @default.
• W4362541676 hasAuthorship W4362541676A5071750897 @default.
• W4362541676 hasAuthorship W4362541676A5077369314 @default.
• W4362541676 hasAuthorship W4362541676A5088521502 @default.
• W4362541676 hasAuthorship W4362541676A5088647899 @default.
• W4362541676 hasConcept C117262875 @default.
• W4362541676 hasConcept C121608353 @default.
• W4362541676 hasConcept C126322002 @default.
• W4362541676 hasConcept C143998085 @default.
• W4362541676 hasConcept C150903083 @default.
• W4362541676 hasConcept C185592680 @default.
• W4362541676 hasConcept C190283241 @default.
• W4362541676 hasConcept C207001950 @default.
• W4362541676 hasConcept C2775975398 @default.
• W4362541676 hasConcept C2776256026 @default.
• W4362541676 hasConcept C502942594 @default.
• W4362541676 hasConcept C55493867 @default.
• W4362541676 hasConcept C71924100 @default.
• W4362541676 hasConcept C86803240 @default.
• W4362541676 hasConcept C98274493 @default.
• W4362541676 hasConceptScore W4362541676C117262875 @default.
• W4362541676 hasConceptScore W4362541676C121608353 @default.
• W4362541676 hasConceptScore W4362541676C126322002 @default.
• W4362541676 hasConceptScore W4362541676C143998085 @default.
• W4362541676 hasConceptScore W4362541676C150903083 @default.
• W4362541676 hasConceptScore W4362541676C185592680 @default.
• W4362541676 hasConceptScore W4362541676C190283241 @default.
• W4362541676 hasConceptScore W4362541676C207001950 @default.
• W4362541676 hasConceptScore W4362541676C2775975398 @default.
• W4362541676 hasConceptScore W4362541676C2776256026 @default.
• W4362541676 hasConceptScore W4362541676C502942594 @default.
• W4362541676 hasConceptScore W4362541676C55493867 @default.
• W4362541676 hasConceptScore W4362541676C71924100 @default.
• W4362541676 hasConceptScore W4362541676C86803240 @default.
• W4362541676 hasConceptScore W4362541676C98274493 @default.
• W4362541676 hasIssue "7_Supplement" @default.
• W4362541676 hasLocation W43625416761 @default.
• W4362541676 hasOpenAccess W4362541676 @default.
• W4362541676 hasPrimaryLocation W43625416761 @default.
• W4362541676 hasRelatedWork W1576752489 @default.
• W4362541676 hasRelatedWork W1975906321 @default.
• W4362541676 hasRelatedWork W1990760558 @default.
• W4362541676 hasRelatedWork W2003006566 @default.
• W4362541676 hasRelatedWork W2062965163 @default.
• W4362541676 hasRelatedWork W2158116775 @default.
• W4362541676 hasRelatedWork W2887920894 @default.
• W4362541676 hasRelatedWork W2991795481 @default.
• W4362541676 hasRelatedWork W3032711494 @default.
• W4362541676 hasRelatedWork W3156932517 @default.
• W4362541676 hasVolume "83" @default.
• W4362541676 isParatext "false" @default.
• W4362541676 isRetracted "false" @default.
• W4362541676 workType "article" @default.